2021 China Life Science Investment Climbs 55% Over 2021's Results
January 10, 2022 at 11:42 AM EST
In 2021, China set impressively higher records in Life Science investing, despite the COVID-19 pandemic. Most categories followed by ChinaBio® hit new all-time highs, signaling high levels of investments in several areas important to China life science companies. According to Greg Scott, Founder and CEO of ChinaBio®, the total value of China life science transactions climbed 55% from 2020's levels, a significant advance under any circumstances, but especially strong given the restrictions of COVID. He delivered the 2021 Report on China Life Science Investment as the Keynote Address at the virtual China Showcase, part of Biotech Showcase™. More details.... Share this with colleagues: // //
